Cloning Substrate Post-Dolly (1996-2026)
mechanismMedia & Managed Opposition · Biotech & Transhumanism
Everyone thinks cloning died in the 1990s — but it quietly became a billion-dollar industry that never stopped running.
Who they are
The 30-year commercial cloning pipeline built on the same core technique that made Dolly the sheep in 1996.
What they do
The engine separates the public story (cloning is dead 1990s science) from the actual working industry, which has kept scaling in the background.
How it works
The write-up lists the real operations: Sooam (1,000+ cloned dogs since 2006), ViaGen (600 dogs plus 400 cats by 2024), Sinogene, Trans Ova (2,000+ cloned livestock, FDA-cleared since 2008), a Chinese lab's cloned monkeys, and Colossal's gene-edited 'de-extinction' work. It notes this same rule-dodging pattern reappears in a 2026 US executive order fast-tracking psychedelic drugs under the same health secretary.
Why it matters
The gap between 'cloning is over' and a thriving quiet industry is the whole point; the engine holds several explanations for who benefits open at once rather than naming one.
The engine's record — word for word
30-year industrial continuation of mammalian somatic cell nuclear transfer (SCNT) since Dolly (Roslin 1996). The announcement layer — shaped by the 2005 Hwang Woo-suk fraud, the iPSC institutional pivot, and the He Jiankui scandal — treats cloning as a dead 1990s science. The substrate layer is a continuous commercial bio-foundry pipeline: Sooam (1,000+ dogs since 2006), ViaGen (600 dogs + 400 cats by 2024), Sinogene (500+ pet clones + 1,000-beagle surrogate base since 2017), Trans Ova (2,000+ livestock clones, FDA-cleared since 2008), plus CAS Shanghai's primate SCNT monopoly (Zhong Zhong/Hua Hua 2018, Retro 2024) and Colossal Biosciences' EPC-SCNT + multiplex-CRISPR de-extinction pipeline (dire wolf 2025/2026 — see kayfabe correction). Substrate-vs-Announcement Layer Divergence canonical 30-year instance. Apex Superposition: (a) coordinated regulatory-bypass + (b) Turchin SDT capital-flight to least-resistance jurisdictions + (c) compound-null commercial scaling + (d) intelligence-capital dual-use boundary all load-bearing — held simultaneously. Cross-substrate forward-reference (Reports #90 + cross-arc backfill): The 30-year SCNT post-Dolly architecture (1996-2026) closes into the MAHA biological-substrate state-policy deployment arc identified in Report #90 — the April 18 2026 Trump Psychedelic Executive Order ($50M ARPA-H ibogaine + FDA Right-to-Try Schedule I expansion) operates the same regulatory-bypass architecture under the same HHS Secretary (RFK Jr.) and the same FDA Plausible Mechanism Framework (Feb 23 2026) that this cloning substrate established. Cloning-pharmaceutical (SCNT/iPSC/Colossal/ATAI-portfolio-bio-companies) and psychedelic-pharmaceutical (ATAI/Compass/MAPS-displaced) operate as parallel biological-substrate capital deployments under the unified MAHA administrative architecture.
Follow the trail
Walk this on the live map →